5 matches for your search in the start-up spotlight
rss
06-Jun-2024
QUANTRO Therapeutics, aSpin-out from the research institutes IMBA and IMP in Vienna, announced that the company has reached a key milestone in its joint R&D program with Boehringer Ingelheim. In successfully applying QUANTRO’s proprietary QUANTROseq® Transcriptional Fingerprint technology, all ...
New technology uses living bacteria to fight cancer
28-Nov-2023
The biotech company T3 Pharmaceuticals, a spin-off from the University of Basel, is being acquired by the German pharmaceutical company Boehringer Ingelheim. T3 Pharma has developed a novel technology that uses live bacteria to deliver therapeutic proteins to cancer cells and the tumor ...
Boehringer Ingelheim and Biotech Startup enter a strategic collaboration
29-Nov-2021
Prime Vector Technologies (PRIME), a Biotech Startup focusing on the development of viral vector based vaccines, and Boehringer Ingelheim, a leading global research-based pharmaceutical company, announce that they have entered a strategic collaboration, option and licence agreement. The ...
Boehringer Ingelheim Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates
14-Dec-2020
Boehringer Ingelheim announced the signing of a binding agreement for acquiring all shares of NBE-Therapeutics, a private, clinical-stage Swiss biotechnology company focused on antibody-drug conjugates and advancing targeted cancer therapies derived from its immune stimulatory iADC™ platform. ...
17-Jul-2019
Boehringer Ingelheim announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first in class therapeutic cancer vaccines derived from its technology platform KISIMA. AMAL’s lead vaccine ATP128 is currently ...
